1,2-Benzisoxazole Phosphorodiamidates as Novel Anticancer Prodrugs Requiring Bioreductive Activation

Journal of Medicinal Chemistry

Volumn 46, Issue 25, 2003, Pages 5428-5436

  Jain, Monish ^a   Kwon, Chul Hoon ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1,2 BENZISOXAZOL 3 YL)ETHYL N,N BIS(2 CHLOROETHYL)PHOSPHORODIAMIDATE; 2 (1,2 BENZISOXAZOL 3 YL)ETHYL N,N,N',N' TETRAMETHYLPHOSPHORODIAMIDATE; 2 (5 NITRO 1,2 BENZISOXAZOL 3 YL)ETHYL N,N BIS(2 CHLOROETHYL)PHOSPHORODIAMIDATE; 2 (6 METHOXY 1,2 BENZISOXAZOL 3 YL)ETHYL N,N BIS(2 CHLOROETHYL)PHOSPHORODIAMIDATE; 3 ETHYL 1,2 BENZISOXAZOLE; ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; IMINE; ISOXAZOLE DERIVATIVE; KETONE; NITROGEN; OXYGEN; PHENOBARBITAL; PHOSPHORAMIDE MUSTARD; PROADIFEN; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CHEMICAL BOND; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG HYDROLYSIS; HUMAN; LIVER; MICROSOME; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE; CRICETINAE; CRICETULUS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOXAZOLES; MICROSOMES, LIVER; NADP; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; PHOSPHORAMIDE MUSTARDS; PRODRUGS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0345412552     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020581y     Document Type: Article

References (35)

1. Brown, J. M. The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1999, 59, 5863-5870.
2. Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors: Opportunities (and Problems) for cancer therapy. Cancer Res. 1998, 58, 1408-1416.
3. Oostween, E. A.; Speckamp, W. N. Mitomycin analogues I. Indolequinones as (potential) bisalkylating compounds. Tetrahedron 1987, 43, 255-262.
4. Naylor, M. A.; Swann, E.; Everett, S. A.; Jaffar, M.; Nolan, J.; Robertson, N.; Lockyer, S. D.; Patel, K. B.; Dennis, M. F.; Stratford, M. R. L. ; Wardman, P.; Adams, G. E.; Moody, C. J.; Stratford, I. J. Indolequinone antitumor agents: Reductive activation and elimination from (5-methoxy-l-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. J. Med. Chem. 1998, 41, 2720-2731.
5. Brenner, J. C. M. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: With particular reference to in vivo methods of evaluation. Cancer Metastasis Rev. 1993, 12, 177-193.
6. Tercel, M.; Wilson, W. R.; Anderson, R. F.; Denny, W. A. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J. Med. Chem. 1996, 39, 1084-1094.
7. Zeman, E. M.; Brown, J. M.; Lemmon, M. J.; Hirst, V. K.; Lee, W. W. SR4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 1986, 12, 1239-1242.
8. Denny WA, Wilson WR. Tirapazamine: A bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin. Investig. Drugs 2000, 9 (12), 2889-901.
9. Sun, Z.-Y.; Botros, E.; Su, A.-D.; Kim, Y.; Wang, E.; Baturay, N.; Kwon, C.-H. Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins. J. Med. Chem. 2000, 43 (22), 4160-4168.
10. Mulcahy, R. T.; Gipp, J. J.; Schmidt, J. P.; Joswig, C.; Borch, R. F. Nitrobenzyl phosphorodiamidates as potential hypoxia-selective agents. J. Med. Chem. 1994, 37 (11), 1610-1615.
11. Flader, C.; Liu, J.; Borch, R. F.; Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase. J. Med. Chem. 2000, 43, 3157-3167.
12. Borch, R. F.; Liu, J.; Schmidt, J. P.; Marakowits, J. T.; Joswig, C.; Gipp, J. J.; Mulcahy, R. T. Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents. J. Med. Chem. 2000, 43, 2258-2265.
13. Workman, P.; Stratford, I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer and Metastasis Reviews 1993, 12, 73-82.
14. Workman, P. Bioreductive mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22 (4), 631-637.
15. Stiff, D. D.; Zemaitis, M. A.; Metabolism of the anticonvulsant agent zonisamide in the rat. Drug Metab. Dispos. 1990, 18 (6), 888-894.
16. Stiff, D. D.; Robicheau, J. T.; Zemaitis, M. A. Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative. Xenobiotica 1992, 22 (1), 1-11.
17. Nakasa, H.; Komiya, M.; Ohmori, S.; Rikihisa, T.; Kiuchi, M.; Kitada, M. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol. Pharmacol. 1993, 44, 216-221.
18. Nakasa, H.; Komiya, M.; Ohmori, S.; Rikisha, T.; Kitada, M. Rat liver microsomal cytochrome P450 responsible for reductive metabolism of zonisamide. Drug Metab. Dispos. 1993, 21 (5), 777-781.
19. Nakasa, H.; Ohmori, S.; Kitada, M. Formation of 2-sulphamoylacetylphenol from zonisamide under aerobic conditions in rat liver microsomes. Xenobiotica 1996, 26 (5), 495-501.
20. Nakasa, H.; Nakamura, H.; Ono, S.; Tsutsui, M.; Kiuchi, M.; Ohmori, S.; Kitada, M. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur. J. Clin. Pharmacol. 1998, 54, 177-183.
21. Sugihara, K.; Kitamura, S.; Tatsumi, K. Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab. Dispos. 1996, 24 (2), 199-202.
22. Sladek, N. E. Metabolism of oxazaphosphorines. Pharm. Ther. 1988, 37, 301-355
23. Ludeman, S. M. The chemistry of the metabolites of cyclophosphamide. Curr. Pharm. Des. 1999, 5, 627-643.
24. Ludeman, S. M.; Boyd, V. L.; Regan, J. B.; Gallo, K. A.; Zon, G.; Ishii, K. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of " phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide. J. Med. Chem. 1986, 29, 716-727.
25. Mustafa, A.; Hsihmat, O. H.; Zayed, S. M. A. D.; Nawar, A. A. Experiments with substituted (3,2-c)-pyranyl-2,10-diones and benzopyranyl-(3,2-c)pyran-2,8-diones. Tetrahedron 1963, 19, 1831-1839.
26. Gianella, M.; Gualtieri, F.; Melchiorre, C. Benzisoxazole and benisothiazole analogues of auxin. Phytochemistry 1971, 10, 539-544.
27. Uno, H.; Kurokawa, M.; Natsuka, K.; Yamato, Y.; Nishimura, H. Studies on 3-substituted 1,2-benzisoxazole derivatives. I. Chem. Pharm. Bull. 1976, 24 (4), 632-643.
28. Uno, H.; Kurokawa, M. Studies on 3-substituted 1,2-benzisoxazole derivatives V. Electrophilic substitution of 1,2-benzisoxazole-3-acetic acid. Chem. Pharm. Bull. 1978, 26 (11), 3498-3503.
29. Villalobos, A.; Blake, J. F.; Biggers, C. K.; Butler, T. W.; Chapin, D. S.; Chen, Y. L.; Ives, J. L.; Jones, S. B.; Liston, D. R.; Nagel, A. A.; Nason, D. M.; Nielsen, J. A.; Shalaby, I. A.; White, W. F. Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase. J. Med. Chem. 1994, 37, 2721-2734.
30. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82 (13), 1107-1112.
31. Jain, M. Design, synthesis and evaluation of mechanistic analogues of aldophosphamide as novel anticancer prodrugs. Master's Thesis, St. John's University, New York, 1994.
32. Kwon, C.-H.; Moon, K.-Y.; Baturay, N.; Shirota, F. Chemically stable, lipophilic prodrugs of phosphoramide mustard as potential anticancer agents. J. Med. Chem. 1991, 34 (2), 588-592.
33. Keyes, S. R.; Francasso, P. M.; Heimbrook, D. C.; Rockwell S.; Sliger, S. G.; Sartorelli, A. C. Role of NADPH: Cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res. 1984, 44, 5638-5643.
34. Onderwater, R. C.; Goeptar, A. R.; Levering, P. R.; Vos, R. M.; Konings, P. N.; Doehmer, J.; Commandeur, J. N.; Vermeulen, N. P. The use of macroporous microcarriers for the large-scale growth of V79 cells genetically designed to express single human cytochrome P450 isoenzymes and for the characterization of the expressed cytochrome P450. Protein Expr. Purif. 1996, 8 (4), 439-46.
35. McGregor, D. B.; Edwards, I.; Wolf, C. R.; Forrester, L. M.; Caspary, W. J. Endogenous xenobiotic enzyme levels in mammalian cells. Mutat. Res. 1991, 261 (1), 29-39.